AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...
Robert Michael will replace former CEO Richard Gonzalez, marking the official end to Gonzalez’s long reign at the pharma ...
4d
Hosted on MSNAbbVie Just Paid Investors: Here’s How Much They ReceivedAbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...
AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results